In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor

Virchows Archiv

Volumn 464, Issue 4, 2014, Pages 495-503

  Gao, Ling ^a   Yue, Michael M ^a   Davis, Jennifer ^a   Hyjek, Elisabeth ^a   Schuger, Lucia ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biopsy; Estrogen receptor; Explanted lung; Lymphangioleiomyomatosis; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY HMB 45; PROGESTERONE RECEPTOR; SMOOTH MUSCLE ANTIBODY;

ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIGITAL IMAGING; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LUNG LYMPHANGIOLEIOMYOMATOSIS; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; OPEN LUNG BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SPECTROSCOPY;

ADULT; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; RECEPTORS, PROGESTERONE;

EID: 84899095594     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1559-9     Document Type: Article

References (64)

1. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J (2012) Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 186:1210-1212
2. Harari S, Torre O, Moss J (2011) Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev 20:34-44
3. Cottin V, Archer F, Leroux C, Mornex JF, Cordier JF (2011) Milestones in lymphangioleiomyomatosis research. Eur Respir Rev 20:3-6
4. McCormack FX (2008) Lymphangioleiomyomatosis: a clinical update. Chest 133:507-516
5. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O (2002) Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47:20-28
6. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP (2003) Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167:976-982
7. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J (2004) Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 101:17462-17467
8. Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, Riemenschn W, Matsui K, Travis WD, Moss J (2000) Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch 67:311-329
9. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J (1999) Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 21:327-336
10. Bonetti F, Chiodera P, Pea M, Martignoni G, Bosi F, Zamboni G, Mariuzzi GM (1993) Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB-45 for diagnosis. Am J Surg Pathol 17:1092-1102
11. Hoon V, Thung SN, Kaneko N, Unger PD (1994) HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch Pathol Lab Med 118:732-734
12. Zhe X, Schuger L (2004) Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 52:1537-1542
13. Astrinidis A, Henske EP (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24:7475-7481
14. Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2:R251-R258
15. Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345-1356
16. Hohman DW, Noghrehkar D, Ratnayake S (2008) Lymphangioleiomyomatosis: A review. Eur J Intern Med 19:319-324
17. Chorianopoulos D, Stratakos G (2008) Lymphangioleiomyomatosis and tuberous sclerosis complex. Lung 186:197-207
18. Bittman I, Rolf B, Amann G, Lohrs U (2003) Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 34:95-98
19. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP (2001) The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med 163:253-258
20. Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97:6085-6090
21. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-808
22. European chromosome 16 tuberous sclerosis consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305-1315
23. Castro AF, Rebhun JF, Clark GG, Quilliam LA (2003) Rheb binds TSC2 and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 278:32493-32496
24. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457-1466
25. Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829-1834
26. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D et al (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578-581
27. Tomasoni R, Mondino A (2011) The tuberous sclerosis complex: balancing proliferation and survival. Biochem Soc Trans 39:466-471
28. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151
29. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595-1606
30. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J (2011) Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 154:797-805
31. Cohen MM, Freyer AM, Johnson SR (2009) Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med 103:766-772
32. Saleh Gargari S, Hantoushzadae S, Mohamadi F, Jafar-Abadi M (2009) Pregnancy complicated by lymphangioleiomyomatosis. Arch Iran Med 12:182-185
33. Yano S (2002) Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 57:1085-1086
34. Matsui K, Takeda K, Yu ZX, Valencia J, Travis WD, Moss J, Ferrans VJ (2000) Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med 161:1002-1009
35. Matsui K, Tatsuguchi A, Valencia J, Zx Y, Bechtle J, Beasley MB, Avila N, Travis WD, Moss J, Ferrans VJ (2000) Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 31:1242-1248
36. Flavin RJ, Cook J, Fiorentino M, Bailey D, Brown M, Loda MF (2011) β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. Am J Clin Pathol 135:776-782
37. Wakamiya T, Sugita Y, Hashiguchi M, Iwasaka T, Tokunaga O (2011) Tuberous sclerosis complex associated with papillary serous carcinoma of the peritoneum, lymphangioleiomyomatosis, and angiomyolipoma. Case Report Pathol 2011:564260
38. Mitani K, Kumasaka T, Takemura H, Hayashi T, Gunji Y, Kunogi M, Akiyoshi T, Takahashi K, Suda K, Seyama K (2009) Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. Acta Cytol 53:402-409
39. Pan LH, Ito H, Kurose A, Yamauchi K, Inoue H, Sawai T (2003) Pulmonary lymphangioleiomyomatosis: a case report with immunohistochemical details and DNA analysis. Tohoku J Exp Med 199:119-126
40. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP (2009) Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A 106:2635-2640
41. Denoo X, Hermans G, Degives R, Foidart JM (1999) Successful treatment of pulmonary lymphangioleiomyomatosis with progestins: a case report. Chest 115:276-279
42. Baldi BG, Medeiros Junior P, Pimenta SP, Lopes RI, Kairalla RA, Carvalho CR (2011) Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis. J Bras Pneumol 37:375-379
43. Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J (2008) Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 133:448-454
44. Schiavina M, Contini P, Fabiani A, Cinelli F, Di Scioscio V, Zompatori M, Campidelli C, Pileri SA (2007) Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis 24:39-50
45. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J (2004) Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126:1867-1874
46. Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, Cordier JF (1999) Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires (GERMOP). Medicine (Baltimore) 78:321-337
47. Liang YJ, Hao Q, Zhang HM, Wu YZ, Wang JD (2012) Insulin-like growth factors in endometrioid adenocarcinoma: correlation with clinico-pathological features and estrogen receptor expression. BMC Cancer 12:262
48. Mufudza C, Sorofa W, Chiyaka ET (2012) Assessing the effects of estrogen on the dynamics of breast cancer. Comput Math Methods Med 2012:473572
49. Badri KR, Gao L, Hyjek E, Schuger N, Schuger L, Qin W, Chekaluk Y, Kwiatkowski DJ, Zhe X (2013) Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med 187:663-665
50. Yu J, Astrinidis A, Howard S, Henske EP (2004) Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 286:L694-L700
51. Ueng SH, Liu HP, Wu YC, Tsai YH, Lin HC, Lin MC, Lim KE, Huang SF (2004) Pulmonary lymphangioleiomyomatosis: a clinicopathological analysis of ten cases. Chang Gung Med J 27:201-209
52. Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J (2012) Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol 7:27
53. van der Horst PH, Wang Y, Vandenput I, Kühne LC, Ewing PC, van Ijcken WF, van der Zee M, Amant F, Burger CW, Blok LJ (2012) Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One 7:e30840
54. Wang Y, van der Zee M, Fodde R, Blok LJ (2010) Wnt/Β-Catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget 1:674-684
55. Wang Y, Hanifi-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken P, Veldscholte J, van Doorn HC, Ewing PC, Kim JJ, Grootegoed JA, Burger CW, Fodde R, Blok LJ (2009) Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 15:5784-5793
56. Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, Giulianelli S, Cerliani JP, Wargon V, Molinolo A (2009) The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16:333-350
57. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
58. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427
59. Axlund SD, Sartorius CA (2012) Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol 357:71-79
60. Daniel AR, Hagan CR, Lange CA (2011) Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab 6:359-369
61. Riggio M, Polo ML, Blaustein M, Colman-Lerner A, Lüthy I, Lanari C, Novaro V (2012) PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer. Carcinogenesis 33:509-518
62. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV (2003) Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17:575-588
63. Grunt TW, Mariani GL (2012) Targeting the PI3K/AKT/mTOR pathway in breast cancer. Curr Cancer Drug Targets 21:177-184
64. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP (2011) Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126:113-120